4.5 Review

Functional decline and herpes zoster in older people: an interplay of multiple factors

Journal

AGING CLINICAL AND EXPERIMENTAL RESEARCH
Volume 27, Issue 6, Pages 757-765

Publisher

SPRINGER
DOI: 10.1007/s40520-015-0450-0

Keywords

Coping style; Functional decline; Herpes zoster; Polypharmacy; Postherpetic neuralgia

Funding

  1. Sanofi Pasteur MSD
  2. bioMerieux
  3. Pfizer studies
  4. Merck
  5. Pfizer
  6. Lilly
  7. Sanofi Pasteur
  8. Grunenthal
  9. Adir
  10. Astra Zeneca
  11. Astellas
  12. ECDC
  13. OMS
  14. ViforPharma
  15. Bristol-Myers-Squibb
  16. Janssen
  17. Lundbeck
  18. Naurex
  19. Otsuka
  20. Roche
  21. Servier
  22. Shire
  23. Alcon
  24. Allergan
  25. Bausch Lomb
  26. Santen
  27. Thea

Ask authors/readers for more resources

Herpes zoster is a frequent painful infectious disease whose incidence and severity increase with age. In older people, there is a strong bidirectional link between herpes zoster and functional decline, which refers to a decrement in ability to perform activities of daily living due to ageing and disabilities. However, the exact nature of such link remains poorly established. Based on the opinion from a multidisciplinary group of experts, we here propose a new model to account for the interplay between infection, somatic/psychiatric comorbidity, coping skills, polypharmacy, and age, which may account for the functional decline related to herpes zoster in older patients. This model integrates the risk of decompensation of underlying disease; the risk of pain becoming chronic (e.g. postherpetic neuralgia); the risk of herpes zoster non-pain complications; the detrimental impact of herpes zoster on quality of life, functioning, and mood; the therapeutic difficulties due to multimorbidity, polypharmacy, and ageing; and the role of stressful life events in the infection itself and comorbid depression. This model underlines the importance of early treatment, strengthening coping, and vaccine prevention.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available